SBT-77-7101

About Sonoma Biotherapeutics

Sonoma Biotherapeutics is a private, clinical-stage biotech founded in 2019 and headquartered in Seattle, USA. The company is pioneering a novel class of living cell therapies using engineered regulatory T cells (Tregs) to treat autoimmune and inflammatory diseases, building directly on the Nobel Prize-winning science of its co-founders. With a strong syndicate of blue-chip life science investors, SonomaBio has advanced its lead candidate into Phase 1 trials and is validating its proprietary platform. The company aims to shift the treatment paradigm from chronic symptom management to potential cures in a vast and underserved market.

Therapeutic Areas